RESUMO
Confusion among physicians and patients is increasing regarding the diagnosis and treatment ofLyme borreliosis due to the enormous amount ofambiguous information available and media attention. Some of the dilemmas that physicians encounter are illustrated by 3 patients with a range of symptoms, one of whom was convinced she had Lyme borreliosis. However none of these patients had significant evidence that suggested Lyme borreliosis. Physicians should follow the guidelines developed by the Dutch Institute for Health Care Improvement (CBO) or the Infectious Diseases Society of America rather than 'alternative' guidelines, which are not evidence-based.
Assuntos
Doença de Lyme/diagnóstico , Guias de Prática Clínica como Assunto , Doenças Transmitidas por Carrapatos/diagnóstico , Adolescente , Adulto , Criança , Diagnóstico Diferencial , Medicina Baseada em Evidências , Feminino , Humanos , Doença de Lyme/tratamento farmacológico , Padrões de Prática Médica , Doenças Transmitidas por Carrapatos/tratamento farmacológicoRESUMO
BACKGROUND: Hyponatraemia in adults with bacterial meningitis has been described as a common complication, but its true prevalence and clinical importance are unknown. AIM: To investigate the prevalence, clinical characteristics and consequences of hyponatraemia in bacterial meningitis in adults. DESIGN: Nationwide observational cohort study. METHODS: We prospectively assessed the prevalence and clinical characteristics of hyponatraemia among 696 adults with community-acquired bacterial meningitis. Symptoms and signs on admission, blood and CSF test results, radiological examinations and complications during admission were recorded. RESULTS: Sodium levels were determined at admission in 685/696 episodes of bacterial meningitis (98%). Hyponatraemia (<135 mmol/l) was seen in 208/685 (30%) and was classified as severe (<130 mmol/l) in 38 (6%). Hyponatraemia developed during admission in an additional 53 episodes. Hyponatraemia was not associated with an increase in symptoms, with complications or with unfavourable outcome. Treatment for hyponatraemia was initiated in 16% of episodes, but did not influence its duration. DISCUSSION: Hyponatraemia appears both common and benign in adults with bacterial meningitis. In cases of severe hyponatraemia, we suggest the use of fluid maintenance therapy.
Assuntos
Hiponatremia/epidemiologia , Meningites Bacterianas/complicações , Adulto , Estudos de Coortes , Infecções Comunitárias Adquiridas/complicações , Humanos , Listeria monocytogenes/isolamento & purificação , Neisseria meningitidis/isolamento & purificação , Países Baixos/epidemiologia , Prevalência , Fatores de Risco , Streptococcus pneumoniae/isolamento & purificaçãoRESUMO
Haemophilus influenzae is an uncommon cause of bacterial meningitis in adults. This report describes a prospective evaluation of 16 episodes of community-acquired H. influenzae meningitis in a nationwide study on bacterial meningitis. Predisposing conditions were present in eight (50%) of the 16 episodes; the most common predisposing conditions were otitis or sinusitis (five episodes; 31%) and remote neurosurgery or head trauma (three episodes; 19%). One (6%) episode was fatal and hearing loss occurred in four (25%) episodes. It was concluded that H. influenzae meningitis in adults is a disease with a rather benign clinical course and a relatively good prognosis compared with pneumococcal meningitis.
Assuntos
Infecções Comunitárias Adquiridas/microbiologia , Haemophilus influenzae/classificação , Meningite por Haemophilus/microbiologia , Adulto , Infecções Comunitárias Adquiridas/líquido cefalorraquidiano , Infecções Comunitárias Adquiridas/complicações , Feminino , Perda Auditiva/etiologia , Humanos , Masculino , Meningite por Haemophilus/líquido cefalorraquidiano , Meningite por Haemophilus/complicações , Pessoa de Meia-Idade , Estudos Prospectivos , SorotipagemRESUMO
In order to evaluate characteristics of nosocomial meningitis in adults, we performed a prospective cohort study of 50 episodes of nosocomial bacterial meningitis. These cases were confirmed by culture of cerebrospinal fluid (CSF) in patients aged >16 years. Classic symptoms of bacterial meningitis (headache, neck stiffness and fever) were present in >70% of the episodes, although only a minority (41%) presented with impairment of consciousness. Underlying conditions, such as a history of neurosurgery, recent head injury, CSF leakage or a distant focus of infection, were present in 94% of the episodes. Staphylococcus aureus was the most common pathogen in patients with a history of neurosurgery, causing 10 of 32 episodes (31%). Patients with a distant focus of infection, such as otitis, sinusitis or pneumonia were more likely to have meningitis due to Streptococcus pneumoniae than patients without [six of nine episodes (67%) vs seven of 41 (17%); P=0.01]. Complications occurred in 50% of the episodes and 16% of the patients died. Our study confirms that adults with nosocomial meningitis are a distinct patient group with specific bacterial pathogens, as compared to those with community-acquired bacterial meningitis. Underlying conditions, especially a history of neurosurgery or a distant focus of infection, were present in the large majority of patients, and mortality and morbidity rates were high.
Assuntos
Infecção Hospitalar/microbiologia , Meningites Bacterianas/microbiologia , Adulto , Idoso , Causalidade , Infecção Hospitalar/etiologia , Infecção Hospitalar/mortalidade , Feminino , Escala de Coma de Glasgow , Infecções por Bactérias Gram-Negativas/líquido cefalorraquidiano , Infecções por Bactérias Gram-Positivas/líquido cefalorraquidiano , Humanos , Masculino , Meningites Bacterianas/etiologia , Meningites Bacterianas/mortalidade , Pessoa de Meia-Idade , Países Baixos/epidemiologia , Procedimentos Neurocirúrgicos/efeitos adversos , Estudos Prospectivos , Fatores de RiscoRESUMO
BACKGROUND: In experimental studies, the clinical outcome of acute bacterial meningitis has been related to the severity of the inflammatory process in the subarachnoidal space. Treatment with corticosteroids can reduce this inflammatory response and thereby may improve outcome. We conducted a meta-analysis of randomised controlled trials (RCTs) of adjuvant corticosteroids in the treatment of acute bacterial meningitis. OBJECTIVES: We conducted a systematic review examining the efficacy and safety of adjuvant corticosteroid therapy in acute bacterial meningitis. SEARCH STRATEGY: In this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2006); MEDLINE (1966 to July 2006); EMBASE (1974 to June 2006); Current Contents (2001 to June 2006); and reference lists of all articles. We also contacted manufacturers and researchers in the field. SELECTION CRITERIA: Eligible published and non-published RCTs on corticosteroids as adjuvant therapy in acute bacterial meningitis. Patients of any age and in any clinical condition, treated with antibacterial agents and randomised to corticosteroid therapy (or placebo) of any type, could be included. At least case fatality rate or hearing loss had to be recorded for inclusion. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted data. Adverse effects were collected from the trials. Additional analyses were performed for children and adults, causative organisms, and low-income and developed countries. MAIN RESULTS: Eighteen studies involving 2750 people were included. Overall, adjuvant corticosteroids were associated with lower case fatality (relative risk (RR) 0.83, 95% CI 0.71 to 0.99), lower rates of severe hearing loss (RR 0.65, 95% CI 0.47 to 0.91) and long-term neurological sequelae (RR 0.67, 95% CI 0.45 to 1.00). In children, corticosteroids reduced severe hearing loss (RR 0.61, 95% CI 0.44 to 0.86). In adults, corticosteroids gave significant protection against death (RR 0.57, 95% CI 0.40 to 0.81) and short-term neurological sequelae (RR 0.42, 95% CI 0.22 to 0.87). Subgroup analysis for causative organisms showed that corticosteroids reduced mortality in patients with meningitis due to Streptococcus pneumoniae (RR 0.59, 95% CI 0.45 to 0.77) and reduced severe hearing loss in children with meningitis due to Haemophilus influenzae (RR 0.37, 95% CI 0.20 to 0.68); subgroup analysis for patients with meningococcal showed a nonsignificant favourable trend in mortality (RR 0.71, 95% CI 0.31 to 1.62). Sub analyses for high-income and low-income countries of the effect of corticosteroids on mortality showed RRs of 0.83 (95% CI 0.52 to 1.05) and 0.87 (95% CI 0.72 to 1.05), respectively. Corticosteroids were protective against short-term neurological sequelae in patients with bacterial meningitis high-income countries (RR 0.56, 95% CI 0.3 to 0.84); in low-income countries this RR was 1.09 (95% CI 0.83 to 1.45). For children with bacterial meningitis admitted in high-income countries, corticosteroids showed a protective effect of on severe hearing loss (RR 0.61, 95% CI 0.41 to 0.90) and favourable point estimates for severe hearing loss associated with non-Haemophilus influenzae meningitis (RR 0.51, 95% CI 0.23 to 1.13) and short-term neurological sequelae (RR 0.72, 95% CI 0.39 to 1.33). For children in low-income countries, the use of corticosteroids was neither associated with benefit nor with harmful effects. Overall, adverse events were not increased significantly with the use of corticosteroids. AUTHORS' CONCLUSIONS: Overall, corticosteroids significantly reduced rates of mortality, severe hearing loss and neurological sequelae. In adults with community-acquired bacterial meningitis, corticosteroid therapy should be administered in conjunction with the first antibiotic dose. In children, data support the use of adjunctive corticosteroids in children in high-income countries. We found no beneficial effect of corticosteroids for children in low-income countries.
Assuntos
Anti-Inflamatórios/uso terapêutico , Glucocorticoides/uso terapêutico , Meningites Bacterianas/tratamento farmacológico , Adolescente , Criança , Dexametasona/uso terapêutico , Perda Auditiva/etiologia , Perda Auditiva/prevenção & controle , Humanos , Meningites Bacterianas/complicações , Prednisolona/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
Two men aged 39 and 38 who had had unprotected insertive and receptive anal sexual contact with men are presented: one had paralysis of the right half of his face and the other man had erythematous macules on the palms of his hands and the soles of his feet as well as partial alopecia, earache and progressive loss of hearing in his left ear. The latter one was also HIV-seropositive and on antiretroviral medication. Syphilitic meningitis was diagnosed in both men. The 2 patients recovered after being treated with intravenous benzyl penicillin. Syphilitic meningitis is a complication seen during the early stages of a syphilis infection. Since the introduction of penicillin it has become a rare disease. Early diagnosis is of importance since syphilitic meningitis has irreversible sequelae.
Assuntos
Doenças dos Nervos Cranianos/etiologia , Homossexualidade , Meningite/complicações , Neurossífilis/complicações , Paralisia/etiologia , Adulto , Antibacterianos/uso terapêutico , Doenças dos Nervos Cranianos/complicações , Infecções por HIV/complicações , Humanos , Masculino , Meningite/diagnóstico , Meningite/tratamento farmacológico , Neurossífilis/diagnóstico , Neurossífilis/tratamento farmacológico , Penicilina G/uso terapêutico , Resultado do TratamentoRESUMO
Six AIDS patients with progressive cytomegalovirus (CMV) polyradiculomyelitis were treated with ganciclovir in an open study. The diagnosis was based on the presence of a distinct clinical syndrome with progressive flaccid paraparesis, preserved proprioception and urinary retention with specific cerebrospinal fluid (CSF) findings. Ganciclovir therapy, 5-10 mg/kg per day, instituted 3-6.5 weeks after onset of symptoms, was ineffective in four patients with severe paraparesis. One patient developed CMV polyradiculomyelitis while receiving ganciclovir and further deteriorated during foscarnet therapy. One patient however, showing minor paresis of one leg, improved after institution of ganciclovir therapy 1 week after onset of symptoms. It is concluded that a presumptive diagnosis of CMV polyradiculomyelitis can be made on the basis of distinct clinical findings and CSF pleocytosis with predominance of polymorphonuclear leukocytes in patients with AIDS. Ganciclovir therapy does not appear to be beneficial for patients with advanced paresis in the doses used. Further investigations are needed in order to determine if early intervention with ganciclovir, when paresis is mild, or higher doses in advanced paresis, might be of some benefit.
Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Infecções por Citomegalovirus/tratamento farmacológico , Ganciclovir/uso terapêutico , Mielite/tratamento farmacológico , Polirradiculoneuropatia/tratamento farmacológico , Adulto , Humanos , Pessoa de Meia-IdadeRESUMO
OBJECTIVE: To assess the clinical presentation and course of the AIDS dementia complex (ADC). DESIGN: Retrospective study of a consecutive series of symptomatic HIV-1-infected patients [Centers for Disease Control and Prevention (CDC) stages IVA, B, C and D] evaluated for neurological symptoms between 1982 and 1992. SETTING: An academic referral centre for AIDS. PATIENTS: A total of 536 symptomatic HIV-1-infected patients evaluated for neurological symptoms between 1982 and 1992. INTERVENTIONS: Zidovudine treatment, which was introduced in The Netherlands on 1 May 1987 for patients with severe symptoms of HIV infection (CDC stages IVA, B, C and D). MAIN OUTCOME MEASURES: Diagnosis of ADC and CD4 cell count, clinical features, neuropsychological abnormalities, computed tomography (CT) and magnetic resonance imaging (MRI) abnormalities, cerebrospinal fluid (CSF) findings and course in patients with ADC. RESULTS: ADC was diagnosed in 40 out of 536 (7.5%) immunosuppressed, neurologically symptomatic HIV-1-infected patients in CDC stage IV, and was the AIDS-defining illness in six. The mean CD4 cell count of the 40 patients with ADC was 109 x 10(6)/l. Neuropsychological abnormalities in 15 out of 17 patients tested were in accordance with subcortical dementia. On CT scan of the brain, 70% showed no or only mild cortical atrophy. MRI was more sensitive than CT scan for detecting white matter abnormalities (73 versus 35%; P = 0.02). CSF examination showed mononuclear pleocytosis in 25%, protein level increase in 55%, and HIV-1 p24 core protein in 38% (13 out of 34). The mean survival was 6.7 months in the 40 ADC patients, but 4 months in 20 patients who had never used zidovudine, compared with 14.8 months in 10 patients who started zidovudine after they were classified as having ADC (P < 0.001). Three of these 10 patients improved remarkably, and two slightly, after starting zidovudine. ADC developed after discontinuation of zidovudine in nine patients. Only one patient developed ADC while receiving 600 mg zidovudine. CONCLUSIONS: MRI is more sensitive than CT for detecting white matter abnormalities. To date, there is no specific or sensitive CSF marker for ADC. Zidovudine may improve symptoms and prolong survival in patients with ADC, which rarely developed with continued zidovudine use in our study.
Assuntos
Complexo AIDS Demência/diagnóstico , HIV-1 , Complexo AIDS Demência/tratamento farmacológico , Complexo AIDS Demência/epidemiologia , Adulto , Líquido Cefalorraquidiano/química , Líquido Cefalorraquidiano/citologia , Líquido Cefalorraquidiano/microbiologia , Feminino , Seguimentos , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Países Baixos/epidemiologia , Estudos Retrospectivos , Fatores de Tempo , Tomografia Computadorizada por Raios X , Zidovudina/uso terapêuticoRESUMO
OBJECTIVE: We conducted a comparison of itraconazole versus amphotericin B plus flucytosine in the initial treatment of cryptococcal meningitis in patients with AIDS and established the efficacy of itraconazole as maintenance treatment. DESIGN: The trial was a prospective, randomized, and non-blinded study. SETTING: The study was performed at an academic centre for AIDS, Amsterdam, The Netherlands. PATIENTS, PARTICIPANTS: Twenty-eight HIV-1-seropositive men with a presumptive diagnosis of cryptococcal meningitis, randomized between 5 February 1987 and 1 January 1990, were included for analysis. INTERVENTIONS: Oral itraconazole (200 mg twice daily), versus amphotericin B (0.3 mg/kg daily) intravenously plus oral flucytosine (150 mg/kg daily) was administered for 6 weeks followed by maintenance therapy with oral itraconazole (200 mg daily) to all patients. MAIN OUTCOME MEASURES: Outcome measures were a complete or partial response, recrudescence and relapse. RESULTS: A complete response was observed in five out of the 12 patients who completed 6 weeks of initial treatment with itraconazole versus all 10 patients who completed treatment with amphotericin B plus flucytosine (P = 0.009). A partial response was observed in seven out of the 14 patients assigned to itraconazole. During maintenance therapy, recrudescence (n = 6) or relapse (n = 1) occurred in seven out of the 12 patients initially assigned to itraconazole, whereas two relapses occurred among nine patients initially treated with amphotericin B plus flucytosine (P = 0.22); recurrence of clinical symptoms was significantly related to a positive cerebrospinal fluid culture at 6 weeks (P = 0.003). CONCLUSION: Itraconazole is less effective compared with amphotericin B plus flucytosine in achieving a complete response in initial therapy in AIDS patients with cryptococcal meningitis.
Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Antifúngicos/uso terapêutico , Cetoconazol/análogos & derivados , Meningite Criptocócica/tratamento farmacológico , Infecções Oportunistas/tratamento farmacológico , Adulto , Anfotericina B/administração & dosagem , Anfotericina B/uso terapêutico , Antifúngicos/efeitos adversos , Antifúngicos/sangue , Quimioterapia Combinada , Flucitosina/administração & dosagem , Flucitosina/uso terapêutico , Humanos , Itraconazol , Cetoconazol/efeitos adversos , Cetoconazol/sangue , Cetoconazol/uso terapêutico , Masculino , Meningite Criptocócica/complicações , Pessoa de Meia-Idade , Infecções Oportunistas/complicações , Estudos Prospectivos , Análise de SobrevidaRESUMO
Six HIV-antigenaemic patients with AIDS or AIDS-related complex were studied to assess the effect of treatment with low-dose zidovudine (250 mg) in 6-hourly doses on HIV antigen (HIV-Ag) levels in cerebrospinal fluid (CSF). HIV-Ag was detected in CSF of three patients before treatment. These patients became CSF HIV-Ag-negative within 8 weeks of treatment. One initially CSF HIV-Ag-negative patient became strongly CSF HIV-Ag-positive during interruption of zidovudine treatment; CSF HIV-Ag disappeared again after treatment was restarted. None of our patients showed a significant neurological improvement during the study. These results show that low-dose zidovudine can suppress viral expression in CSF. Whether suppression of viral replication can prevent future HIV-related neurological disease remains to be investigated.
Assuntos
Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Antígenos Virais/líquido cefalorraquidiano , HIV/imunologia , Timidina/análogos & derivados , Síndrome da Imunodeficiência Adquirida/líquido cefalorraquidiano , Síndrome da Imunodeficiência Adquirida/imunologia , Doenças do Sistema Nervoso Central/líquido cefalorraquidiano , Doenças do Sistema Nervoso Central/tratamento farmacológico , Doenças do Sistema Nervoso Central/imunologia , HIV/efeitos dos fármacos , HIV/fisiologia , Antígenos HIV , Humanos , Masculino , Timidina/administração & dosagem , Timidina/uso terapêutico , Fatores de Tempo , Replicação Viral/efeitos dos fármacos , ZidovudinaRESUMO
Human immunodeficiency virus type-1 (HIV-1) antigen was assayed in paired serum/cerebrospinal fluid (CSF) specimen from 85 adults and 58 children with acquired immunodeficiency syndrome and was compared with clinical neurological status. A quantitative comparison of HIV-1 antigen levels in matched serum and CSF specimens indicated that HIV-1 antigen expression in these compartments is independent and is correlated with acquired immunodeficiency syndrome dementia complex in adults and progressive encephalopathy in children. In a longitudinal study (n = 47), 16 patients tested positive for HIV-1 antigen in the CSF before (n = 2) or coincident (n = 14) with neurological deterioration. Six patients who tested positive for HIV-1 antigen in the CSF remained neurologically normal for a median duration of follow-up of 11 months. Six of 25 patients who tested negative for HIV-1 antigen in the CSF, subsequently showed neurological deterioration. These data indicate that HIV-1 antigen expression in the CSF is not useful in predicting neurological deterioration.
Assuntos
Síndrome da Imunodeficiência Adquirida/líquido cefalorraquidiano , Antígenos HIV/líquido cefalorraquidiano , Síndrome da Imunodeficiência Adquirida/complicações , Encefalopatias/etiologia , Criança , Pré-Escolar , Demência/etiologia , Humanos , Lactente , Estudos Longitudinais , Doenças do Sistema Nervoso/etiologiaRESUMO
Cytomegalovirus (CMV) polyradiculomyelitis was diagnosed in 4 of 241 consecutive neurologically assessed human immunodeficiency virus type (HIV-1) seropositive patients. CMV-related neurologic disease was suspected on clinical grounds and was subsequently confirmed by CMV culture from cerebrospinal fluid (CSF) and/or CMV in situ hybridization on specific specimens. All four patients showed CSF pleocytosis with predominance of polymorphonuclear leukocytes (PMNs). Retrospective analysis of the results of CSF examination, performed in 143 of 241 patients with neurologic symptoms, showed pleocytosis in 58 of 143 patients. Predominance of PMNs was found in seven patients, including the four with CMV polyradiculomyelitis. It is concluded that in HIV-1 seropositive patients with a clinical diagnosis of polyradiculomyelitis, a predominance of PMNs in CSF could be an indication that the condition is CMV related. This should lead to early diagnosis and institution of specific antiviral therapy.
Assuntos
Síndrome da Imunodeficiência Adquirida/líquido cefalorraquidiano , Infecções por Citomegalovirus/líquido cefalorraquidiano , HIV-1 , Neutrófilos/patologia , Infecções Oportunistas/líquido cefalorraquidiano , Polirradiculoneuropatia/líquido cefalorraquidiano , Síndrome da Imunodeficiência Adquirida/complicações , Adulto , Infecções por Citomegalovirus/complicações , Humanos , Infecções Oportunistas/complicações , Polirradiculoneuropatia/complicaçõesRESUMO
We retrospectively assessed the efficacy of maintenance therapy with pyrimethamine alone in 38 patients with AIDS and central nervous system (CNS) toxoplasmosis. The diagnosis was based on clinical presentation and compatible CT scan abnormalities with subsequent response to therapy. Survival analysis was performed by the product limit method of Kaplan-Meier. Fourteen patients received maintenance therapy with 25 mg pyrimethamine per day (group 1), and 24 patients were treated with 50 mg per day (group 2). The median survival from initiation of maintenance therapy until death or end of the study for the entire study population was 32 weeks. Median survival in group 1 was 28 weeks, as compared with 36 weeks in group 2 (p = 0.34). Relapses occurred in 12 patients, six in group 1 and six in group 2. There was no significant difference in failure-free survival between the two treatment groups (p = 0.09). One patient in group 1 and two patients in group 2 experienced severe toxicity, requiring discontinuation of therapy. All three patients relapsed and died. Two patients in group 2 who stopped treatment on their own initiative also had relapses. Thus, all five patients who discontinued therapy had relapses. Five of 13 patients in group 1 and two of 20 patients in group 2 relapsed during continuous therapy with pyrimethamine (p = 0.13); these seven patients responded to reintroduction of combination therapy (n = 6) or treatment with 50 mg pyrimethamine per day (n = 1). The results of our retrospective analysis suggest that maintenance therapy with oral pyrimethamine, 50 mg per day, in AIDS patients with CNS toxoplasmosis is effective.
Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Infecções Oportunistas/tratamento farmacológico , Pirimetamina/uso terapêutico , Toxoplasmose Cerebral/tratamento farmacológico , Adulto , Quimioterapia Combinada , Feminino , Humanos , Masculino , Estudos Retrospectivos , Sulfadiazina/uso terapêutico , Toxoplasmose Cerebral/complicaçõesAssuntos
Hidrocefalia/etiologia , Sarcoidose/complicações , Adulto , Idoso , Anti-Inflamatórios/uso terapêutico , Feminino , Humanos , Hidrocefalia/diagnóstico , Hidrocefalia/patologia , Linfonodos/patologia , Imageamento por Ressonância Magnética , Masculino , Prednisolona/uso terapêutico , Sarcoidose/diagnóstico , Sarcoidose/patologiaRESUMO
Death following lumbar puncture (LP) is feared by physicians. Many opinions are found in literature on the question whether computed cranial tomography (CT) should be performed before LP, to prevent herniation. These opinions are mainly based on retrospective studies and pathophysiological reasoning. In this review the difficulties in the decision whether we should perform CT before LP are discussed. It is explained that the concept of "raised intracranial pressure" is confusing, and that the less ambiguous terms "brain shift" and "raised CSF pressure" should be used instead. Brain shift is a contraindication to LP, whether CSF pressure is raised or not, and whether papilloedema is present or not. Subsequently, recommendations are offered for indications to perform CT before LP, grouped according to the safety and clinical utility of LP.
Assuntos
Pressão do Líquido Cefalorraquidiano/fisiologia , Encefalocele/diagnóstico por imagem , Encefalocele/prevenção & controle , Hipertensão Intracraniana/complicações , Hipertensão Intracraniana/diagnóstico por imagem , Punção Espinal/efeitos adversos , Tomografia Computadorizada por Raios X/normas , Encéfalo/diagnóstico por imagem , Encéfalo/patologia , Encéfalo/fisiopatologia , Ventrículos Cerebrais/patologia , Ventrículos Cerebrais/fisiopatologia , Diagnóstico Diferencial , Encefalocele/etiologia , Humanos , Hipertensão Intracraniana/diagnóstico , Papiledema/complicações , Papiledema/diagnóstico , Papiledema/fisiopatologia , Fatores de RiscoRESUMO
Seven patients are reported with meningitis due to viridans streptococci. These patients represented 5% of culture-proven cases of bacterial meningitis in adults participating in a prospective multicentre clinical trial evaluating the use of dexamethasone. Meningitis was iatrogenic in three patients: one patient had been treated with endoscopic sclerotherapy for oesophageal varices, and two patients had undergone thermocoagulation of the gasserian ganglion for trigeminal neuralgia in the previous days.
Assuntos
Doença Iatrogênica , Meningites Bacterianas/etiologia , Infecções Estreptocócicas/etiologia , Streptococcus , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Meningites Bacterianas/tratamento farmacológico , Pessoa de Meia-Idade , Infecções Estreptocócicas/tratamento farmacológicoRESUMO
We carried out a meta-analysis of 22 trials to determine the comparative placebo effect of (a) subcutaneous vs. oral and (b) in-hospital vs. at-home administration in the treatment of migraine. The headache relief rates were combined from the placebo arms of these randomised clinical trials assessing the value of sumatriptan in acute treatment of migraine. The main outcome measure was the proportion of patients reclassified from severe or moderate headache severity to no or mild headache severity 2 h after the beginning of treatment. In the oral regimen 222 of 865 patients (25.7%) reported no or mild headache severity after 2 h, compared to 279 of 862 patients (32.4%) of those receiving subcutaneous placebo (6.7% difference; 95% CI 2.4-11.0%). Adjusting for treatment setting and severity of headache at baseline did not change the observed difference. After placebo treatment at home 285 of 1,054 patients (27.0%) reported no or mild headache severity after 2 h, compared to 216 of 673 patients (32.1%) among those receiving placebo in hospital (5.1 % difference; 95% CI 0.6-9.5%). When adjusted for route of administration and severity of headache at baseline, the difference in relief rates between home and hospital setting disappeared. These findings indicate that subcutaneous administration enhances the placebo effect of acute treatment of migraine. Future trials of antimigraine drugs assessing the relative efficacy of various routes of administration should use a double-dummy technique. The interpreting of placebo-controlled trial results must therefore consider that the effect in the drug arm of the trial depends in part on the route of administration.
Assuntos
Transtornos de Enxaqueca/tratamento farmacológico , Placebos/administração & dosagem , Administração Oral , Adulto , Feminino , Hospitalização , Humanos , Injeções Subcutâneas , Masculino , Efeito Placebo , Placebos/farmacologia , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
BACKGROUND: Acute bacterial meningitis remains a disease with high mortality rate, ranging from 10 to 30 percent, despite advances in critical care. It has been estimated that between 5 to 40 percent of all patients can suffer hearing loss. The use of corticosteroids as adjuvant therapy in the treatment of acute bacterial meningitis is controversial despite several controlled clinical trials and three meta-analyses. In particular there are few data on the use of corticosteroids in adult meningitis. OBJECTIVES: We conducted a systematic review examining the efficacy and safety of adjuvant corticosteroid therapy in children and adults with acute bacterial meningitis. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library issue 1, 2003)); MEDLINE (1966 to April 2002); EMBASE (1974 to April 2002); and HEALTHLINE (1988 to April 2002) and Current Contents for trials published before the April 1st 2002, and reference lists of articles. We also contacted manufacturers and researchers in the field. SELECTION CRITERIA: Eligible studies were published or non-published randomised controlled trials on corticosteroids as adjuvant therapy in acute bacterial meningitis. Patients of any age and in any clinical condition, treated with antibacterial agents and randomised to corticosteroid therapy (or placebo) of any type, could be included. At least case fatality rate or hearing loss had to be recorded for inclusion. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. Study authors were contacted for additional information. Adverse effects information was collected from the trials. MAIN RESULTS: Eighteen studies involving 1853 people were included. Overall, adjuvant corticosteroids were associated with lower case fatality (relative risk (RR) 0.76, 95% confidence intervals (CI) 0.59 to 0.98) and lower rates of both severe hearing loss (RR 0.36, 95% CI 0.22 to 0.60) and long-term neurological sequelae (RR 0.66, 95% CI 0.44 to 0.99). In children, corticosteroids reduced severe hearing loss in bacterial meningitis caused by Haemophilus influenzae (RR 0.31, 95% CI 0.15 to 0.62), as well as in meningitis caused by other bacteria than H. influenzae (RR 0.42, 95%CI 0.20 to 0.89). In adults there was a reduction in case-fatality (RR 0.38, 95% CI 0.18 to 0.78), however there were few data. Adverse events were not increased significantly with the use of corticosteroids. REVIEWER'S CONCLUSIONS: Adjuvant corticosteroids are beneficial in the treatment of children with acute bacterial meningitis. The limited data available in adults shows a trend in favour of adjuvant corticosteroids but a definite recommendation must await more studies. ERRATUM: During the review process of this systematic review the results of the European Dexamethasone in Adulthood Bacterial Meningitis Trial were published. (De Gans 2002) In this prospective, randomised, double-blind, multicenter trial, which included 301 adults with bacterial meningitis, treatment with dexamethasone was associated with a reduction in mortality (relative risk of death, 0.48; 95 CI 0.24 to 0.96; p = 0.04). Therefore, dexamethasone should be given to all adults with bacterial meningitis and should be initiated before or with the first dose of antibiotics.
Assuntos
Corticosteroides/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Meningites Bacterianas/tratamento farmacológico , Adolescente , Criança , Dexametasona/uso terapêutico , Perda Auditiva/etiologia , Perda Auditiva/prevenção & controle , Humanos , Meningites Bacterianas/complicações , Prednisolona/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
Mental changes are common in patients with acquired immunodeficiency syndrome (AIDS). Neuropsychological data of 32 patients with AIDS and cognitive symptoms were reviewed. All patients were neurologically examined and ancillary investigations were performed. According to the neuropsychological data three groups could be distinguished: I) 4 patients with dementia and cortical deficits; II) 16 patients with subcortical dementia; III) 12 patients with subcortical cognitive deficits without global intellectual deterioration. AIDS Dementia Complex (ADC) was diagnosed in 12 patients and occurred in all three groups. The most frequent form of dementia in patients with AIDS is of a subcortical type. Impaired memory or reduced psychomotor speed, or both, are common in patients without global intellectual deterioration. ADC seems an unlikely diagnosis in patients with cortical dementia. Neuropsychological examination is important for diagnosing ADC but the diagnosis cannot be made without regarding the neurological findings and ancillary investigations.
Assuntos
Complexo AIDS Demência/psicologia , Complexo AIDS Demência/diagnóstico , Complexo AIDS Demência/tratamento farmacológico , Adulto , Atenção , Humanos , Inteligência , Masculino , Memória , Pessoa de Meia-Idade , Exame Neurológico , Testes Psicológicos , Desempenho Psicomotor , Tomografia Computadorizada por Raios X , Zidovudina/uso terapêuticoRESUMO
A 58-year-old patient suffering from Guillain-Barré syndrome was successfully treated with plasma exchange therapy. Two- and half year later she developed AIDS. The only risk factor of this patient was plasmapheresis and it appeared, retrospectively, that one of the plasma donor samples contained antibodies to HIV. Knowing the exact moment of infection of our patient we documented the transfer of HIV antibodies from donor to patient, a HIV antigen peak two weeks after transmission (reflecting the initial virus replication in the patient) and subsequently the occurrence of patients' HIV antibodies and the reoccurrence of HIV antigen at the moment AIDS was diagnosed.